EUVIMEDEUVIMED entdecken
LeitlinieÜbersichtsarbeitOpen Access · CC BY 4.0

Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors

Andrew Blauvelt, Bruce E Strober, Guy S Eakin, Leah McCormick Howard, Christy Langan, Peter C M van de Kerkhof, Lluís Puig, Mark G Lebwohl, Ricardo Romiti, April W Armstrong, Siew Eng Choon, Ravi Ramessur und 4 weitere

Journal of the American Academy of Dermatology · 2026-03 · 94 (3) · 802-809

DOI: 10.1016/j.jaad.2025.11.033 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of the American Academy of Dermatology, 2026-03. Verfasst von Andrew Blauvelt und 15 weiteren Autor:innen. Beteiligte Einrichtung: Blauvelt Consulting, LLC, Annapolis, Maryland. Electronic address: blauveltconsults@gmail.com. Hauptthemen laut MEDLINE: Psoriasis, Latent Tuberculosis, Interleukin-23, Interleukin-17. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although testing for latent tuberculosis (TB) infection has been standard practice for psoriasis patients being treated with interleukin (IL) 17 or IL-23 inhibitors, evidence for this practice is weak. OBJECTIVES: To review evidence on safety of IL-17 and IL-23 inhibitors in the setting of latent TB infection and to provide a new Joint Position Statement on this topic. METHODS: Experts from the National Psoriasis Foundation and the International Psoriasis Council reviewed evidence regarding progression of latent TB infection to active disease in psoriasis patients receiving IL-17 or IL-23 blockers. A Joint Position Statement was formulated and approved to provide updated guidance to clinicians. RESULTS: 87.5% of the members from the National Psoriasis Foundation Medical Board and International Psoriasis Council approved a new Joint Position Statement regarding psoriasis patients being treated with IL-17 or IL-23 inhibitors, stating that testing for latent TB infection is not required. LIMITATIONS: This position statement allows for exceptions where continued testing for late nt TB infection could be considered, including for patients on concomitant immunosuppressive therapy and for those living in TB endemic areas. CONCLUSION: Psoriasis experts reached consensus that routine testing for latent TB infection is not required in psoriasis patients being treated with IL-17 or IL-23 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisLatent TuberculosisInterleukin-23Interleukin-17Humans

Stichwörter der Autor:innen

IL-17 inhibitorsIL-23 inhibitorsbiologicspsoriasissafetytuberculosis

Substanzen

Interleukin-23Interleukin-17

Autor:innen und Institutionen

  • Blauvelt Consulting, LLC, Annapolis, Maryland. Electronic address: blauveltconsults@gmail.com.
  • Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
  • National Psoriasis Foundation, Alexandria, Virginia.
  • International Psoriasis Council, Santa Rosa, California.
  • International Psoriasis Council, Santa Rosa, California; Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.
  • Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.

Zitieren

APA

Blauvelt, A., Strober, B. E., Eakin, G. S., McCormick Howard, L., Langan, C., van de Kerkhof, P. C. M., Puig, L., Lebwohl, M. G., Romiti, R., Armstrong, A. W., Choon, S. E., Ramessur, R., Gelfand, J. M., Merola, J. F., Winthrop, K. L., & Torres, T. (2026). Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors. Journal of the American Academy of Dermatology, 94(3), 802-809. https://doi.org/10.1016/j.jaad.2025.11.033

Vancouver

Blauvelt A, Strober BE, Eakin GS, McCormick Howard L, Langan C, van de Kerkhof PCM, et al. Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors. Journal of the American Academy of Dermatology. 2026;94(3):802-809. doi:10.1016/j.jaad.2025.11.033

BibTeX
@article{Blauvelt2026,
  author = {Blauvelt, Andrew and Strober, Bruce E and Eakin, Guy S and McCormick Howard, Leah and Langan, Christy and van de Kerkhof, Peter C M and Puig, Lluís and Lebwohl, Mark G and Romiti, Ricardo and Armstrong, April W and Choon, Siew Eng and Ramessur, Ravi and Gelfand, Joel M and Merola, Joseph F and Winthrop, Kevin L and Torres, Tiago},
  title = {Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors},
  journal = {Journal of the American Academy of Dermatology},
  year = {2026},
  volume = {94},
  number = {3},
  pages = {802--809},
  doi = {10.1016/j.jaad.2025.11.033}
}
Kostenlos starten →